公开(公告)号：US20230220065A1

公开(公告)日：2023-07-13

申请号：US18010647

申请日：2021-06-15

Applicant: ACADEMIA SINICA

Inventor： Andrew H.-J. WANG ,  Wen-Chih KUO ,  Cheng-Chung LEE ,  An-Suei YANG

IPC: C07K16/24 ,  A61P35/00 ,  A61K47/26 ,  C12N15/63

CPC classification number: C07K16/245 ,  A61P35/00 ,  A61K47/26 ,  C12N15/63 ,  A61K2039/505

Abstract: Disclosed herein are anti-IL-1β antibodies capable of binding to human IL-1β and blocking its biological activities. Also provided herein are pharmaceutical compositions comprising the anti-IL-1β antibodies and therapeutic and diagnostic uses of such antibodies.

公开(公告)号：US20230233699A1

公开(公告)日：2023-07-27

申请号：US17918947

申请日：2021-04-15

Applicant: ACADEMIA SINICA

Inventor： Andrew H.-J. WANG ,  Cheng-Chung LEE ,  Nai-Shu HSU ,  Wen-Chih KUO

IPC: A61K47/68 ,  A61K47/58 ,  A61K47/54

CPC classification number: A61K47/6803 ,  A61K47/58 ,  A61K47/6889 ,  A61K47/549

Abstract: The present invention relates to oligonucleotide conjugates and preparation and applications thereof. In particular, the present invention relates to an oligonucleotide conjugated to a biomolecule (e.g. an antibody) and/or an agent of interest (e.g. a drug). In certain embodiments, the oligonucleotide of the present invention is a hybridized complex of a single strand oligonucleotide carrying a biomolecule and a complementary strand oligonucleotide bearing an agent of interest where the hybridized nucleotide segment acts as a linker to link the biomolecule and the agent of interest in one molecule.